Therapy for unresectable hepatocellular carcinoma: time for XRT?
Pingpank
James F
JF
Surgery Branch, Center for Cancer Research, National CancerInstitute, National Institutes of Health, Bethesda, Maryland 20892, USA. james_pingpank@nih.gov
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D017093:Liver Failure / Q000453:epidemiology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D011859:Radiography; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis
D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil